Skip to content

Author

Anand Prakash

We have 3 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Efficiency of griseofulvin and plumbagin in mitigating N-nitrosodiethylamine-induced hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) is a globally prevalent malignancy often triggered by oxidative stress and exposure to hepatotoxic agents such as N-nitrosodiethylamine (NDEA), which induces DNA adducts, inflammation, and liver dysfunction. Natural compounds like plumbagin (PL) and griseofulvin (GF) have demonstrated ant...

Ekta Tyagi, Rajabrata Bhuyan, Anand Prakash · 0 citations
Open access Jan 2026

Orbitrap HRMS‐Based Comprehensive Metabolite Characterization of Duvelisib in Cross‐Species Hepatocytes

Duvelisib (DVB), a selective PI3K‐δ/γ inhibitor approved for chronic lymphocytic leukemia, requires detailed metabolic characterization to support early drug development and selection of appropriate toxicology species. Because drug metabolism varies across species, an integrated system such as primary hepatocytes conta...

B. Warkad, Swapnil Sharma, Prakash Niguram et al. · 0 citations
Open access Jul 2026

Targeting breast cancer with 1,2,4-trioxanes: synthesis, cytotoxicity, and molecular docking insights

Density functional theory (DFT) analysis indicated that electrophilicity and electronic softness correlate with cytotoxic potency, highlighting the mechanistic relevance and therapeutic potential of 1,2,4-trioxanes as promising leads for further development as breast cancer therapeutics.

Priyanka Yadav, Monika Shukla, Suryakant Kumar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.